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Summary Methotrexate (MTX) shows consistent cytotoxicity for melanoma cells in vitro but it is ineffective
in clinical use at equivalent concentrations in vivo. This apparent paradox has been investigated by cell culture
techniques and results quantified by cell number. In an in vitro model of high dose MTX therapy followed by
leucovorin rescue (HD-MTX-LCR) there was survival of both melanoma and choriocarcinoma cell lines but
not of an acute lymphocytic leukaemia cell line. The 70H metabolite of MTX was identified by HPLC in
plasma samples of melanoma patients treated by HD-MTX-LCR, in which MTX concentrations 10-5M
were maintained for 24h. However, metabolism per se is unlikely to account for the lack of response to MTX
clinically. In vitro 70H-MTX (10-7-10-6M) was two orders of magnitude less cytotoxic for melanoma than
MTX (0-9-10-8 M). The cellular accumulation of [3H]-MTX, using a rapid gradient centrifuge technique
for separation of melanoma cells from medium, was reduced in the presence of 70H-MTX.
The results suggest that reduced cellular uptake of MTX combined with biochemical rescue of tumour cells
may partially explain the paradoxical lack of clinical response ofmelanoma to the drug.
Reports of clinical results in patients with advanced
malignant melanoma treated with high dose
methotrexate (MTX) therapy suggest a poor rate of
response (Fisher et al., 1979; Karakousis &
Carlson, 1979). These reports do not, however, give
any details of plasma concentrations of MTX
achieved or the period of time over which a high
concentration was maintained. An apparent
paradox to this picture of lack of response to MTX
in vivo is the observation that murine melanoma
cells in vitro are rapidly killed by relatively low
(10-8 M to 10-9M) concentrations of the agent
(Bostock et al., 1979).
Possible explanations for these paradoxical
findings in vivo and in vitro may include the
differences between the MTX concentrations to
which cells are exposed and the possibility that
folinic acid rescue used routinely in vivo may
salvage tumour cells as well as essential marrow
and mucosal elements. Differences in MTX
transport, and metabolism between melanoma cells
in vivo and in vitro may also operate and the
activity of intracellular dihydrofolate reductase, and
the proportion of cells undertaking DNA synthesis
at the time of exposure to methotrexate may also
be important variables. The observation that
dihydrofolate reductase is identical in certain
MTX-resistant and -sensitive wild-type lines of
PGl9 murine melanoma (Bostock et al., 1979)
indicates that qualitative enzyme differences are not
responsible for the acquired resistance in some
melanoma mutants.
We have investigated these variables by a study
in which three patients with advanced malignant
melanoma resistant to other cytotoxic drugs were
treated with high dose MTX. The plasma
concentrations of MTX and MTX metabolites were
measured throughout a 24h period. The
relationship of these in vivo metabolites to those
found in the culture medium surrounding human
and murine melanoma cell lines treated with MTX
in vitro was established. The uptake of the drug by
the cells in culture was also studied in order to
determine whether there was competition by 70H-
MTX for uptake of MTX. When these findings
were established, the ability of leucovorin to rescue
melanoma cells from MTX toxicity was
investigated.
Materials and methods
Clinical studies
Three patients, 2 males and 1 female, with
histologically proven stage III malignant
melanoma, were treated with high dose
methotrexate given by 24h infusion. Plasma MTX
concentrations were monitored by an EMIT assay
during the infusion, to give immediate levels to
assist in patient management, and the rate of
infusion adjusted to maintain the concentration
above 10-6 M. This was achieved in all patients,
with peak concentrations >10- M being observed.
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At the end of each infusion, calcium leucovorin was
given i.v. at a dose of 30mg, thereafter 19mg
was given at 6 hourly intervals until plasma MTX
concentrations fell below 10-6M. In all cases the
patients urine was kept alkaline using sodium
bicarbonate and a fluid load was given at the end
of the infusion. Two of the patients had 2 courses,
all at 3-weekly intervals. No clinical response was
observed.
The same plasma samples were subsequently re-
analysed by high pressure liquid chromatography
(HPLC) in order to determine MTX free from
interference and to quantify 70H-MTX and other
metabolites, if any. All concentrations described in
this paper were determined using the HPLC assay.
In vitro studies
The following cell lines were kindly provided by the
named individuals.
Human melanoma B8 (B0008) and B1O (BOO10)
(Creasey et al., 1979); MEL57 (Dr. C. Sorg,
Universitats Hautklinik, Miinster); MYJ15.
ADLER and KOTLER (Drs Houghton and Lloyd,
Memorial Sloan Kettering Cancer Center, USA).
Murine melanoma The MTX-sensitive strain of the
PG19 cell line (Bostock et al., 1979) was used in
comparative studies.
Human choriocarcinoma BeWo and JaR cell lines
(Prof. K. Bagshawe and colleagues).
Human acute lymphoblastic leukaemia KM3
(Schneider et al., 1977) (Dr. R. Tindle, Beatson
Institute for Cancer Research, Glasgow, Scotland).
Culture details
Except where stated all cultures were grown in
RPMI 1640 medium supplemented with 10% v/v
newborn calf serum (NCS) (Flow Laboratories,
Irvine, Scotland). Different batches of serum
contained folate at widely varying concentrations.
We selected batches which contained 15-25 ngml-1.
The nucleoside content was not investigated.
Incubation was at 370C in a humidified atmosphere
of 5% C02 in air.
Cells were inoculated into 5ml of medium at a
density of 5 x 104 cells per 25cm2 tissue culture
flask. Sterile additions were made as required in
complete medium.
Cultures were inoculated in duplicate and cell
numbers determined by counting on a Coulter
Counter model D with coincidence correction. Prior
to counting, monolayers were suspended by
treatment with a Mg2+- and Ca2+-free buffered salt
solution containing per litre: 154mM Na+, 4.1 mM
K+, 9.6mM HpO -, 141 mM Cl-, 1.1mM glucose
and 0.53mM EDTA, pH 7.4.
Relative cell counts
To compare the response of the cell lines used to
varying concentrations of MTX and 70H-MTX,
cell numbers determined in the experimental flasks
are expressed as a percentage of the number of cells
in the control flasks in the absence of inhibitor.
This value is referred to as a relative cell count,
RCC.
In vitro rescue ofMTX-treated cells
After incubation for defined periods in RPMI 1640
with 10% NCS, containing 10-6M or 10-5M
MTX, the cells were washed twice in serum-free
medium, leucovorin 1pgml-1 was added to the
complete medium and incubation continued at
37°C in 5% CO2 in air for 4-11 days. Adherent
cells were then counted by the standard method
and results expressed as cell numbers.
Measurement of the competition between 70H-MTX
and MTXfor cell uptake
Isolated melanoma cells were incubated in RPMI
1640 containing the appropriate quantity of non-
labelled MTX or 70H-MTX and a constant
amount of [3;5;7'-3H] MTX (IpCiml-1). Following
incubation at 37°C, aliquots containing 5 x 105 cells
were removed at the appropriate time intervals and
the cells separated from medium by centrifuging
through a layer of bromodecanes (S.G. 1.05) as a
discontinuous gradient, using a modification of the
method described by Smith & Pogson (1980).
Contamination of the cell pellet with incubation
medium was calculated from the deposition of
hydroxy [i4C]-methyl inulin (Sp. Act. 0.9pCimg-)
which was added immediately prior to cell
separation as 0.1pCi per ml of each incubation.
Contamination of cell pellets with [14C]-inulin was
<5% of the added amount. Values for MTX
accumulation have been appropriately corrected.
Radiochemicals were purchased from Amersham
International and purity checked by HPLC using a
Nuclear Enterprises Isoflow flow monitor.
Preparation of 70H-MTX
The 7OH-MTX used in these studies was prepared
by a method based on that of Johns & Loo, 1967.
The product was purified chromatographically to
homogeneity using a column of DE52 cellulose,
eluted with 0.6 M ammonium bicarbonate. TheMELANOMA RESPONSE TO METHOTREXATE 673
relevant pooled fractions were freeze-dried to
remove the ammonium bicarbonate. The compound
was stored sterile at -20°C in aqueous solution
and diluted by complete culture medium to the
required concentrations.
Analysis ofculture medium
HPLC was used to analyze the media obtained
from cell cultures incubated in the presence of
MTX and/or 70H-MTX over periods up to 11
days. The medium was deproteinised by heating for
Omin in a boiling water bath, the flocculated
protein removed by high speed centrifugation using
a Beckman microfuge, and the resulting
supernatant injected directly on to a 1Ocm x 4mm
(ID) column of Hypersil ODS (Shandon-Southern
Ltd., Runcorn, Cheshire, UK) and eluted
isocratically using a mobile phase consisting of
methanol: 0.05 M phosphoric acid, 28:72 containing
0.1% hexanesulphonic acid. Detection was at
307nm in an 8,ul flowcell. The flow rate was
1 mlmin 1 (Farid et al., 1983).
Results
Clinical studies
No evidence of clinical response was observed in
the 3 patients studied. For this reason it was agreed
that no further patients would be treated using this
regime. Immediate EMIT analyses, subsequently
checked by HPLC, confirmed that plasma MTX
concentrations were maintained at, or close to,
10 5M throughout the 24h period. The total dose
of MTX administered to each patient during these
periods ranged from 1.3-1.5 g. HPLC analysis of
these samples showed the major MTX metabolite,
70H-MTX, to be present in plasma at
concentrations similar to those reported in patients
with osteogenic sarcoma (Breithaupt et al., 1982)
and that samples obtained after 24h contained
70H-MTX at concentrations exceeding that of
MTX (Figure 1).
In vitro studies
Effect of MTX and 70H-MTX on cell
growth Cloned human malignant melanoma lines
and a murine melanoma line were used to obtain
dose-response profiles at different concentrations of
MTX. Two types of profile were observed (Figure
2) when the relative cell numbers (RCC) were
plotted against the concentration of MTX in the
medium. In the first group of profiles cell growth
was arrested at a 50% RCC value of 10-8-
10-9M MTX. This group comprised the cell lines
PGl9, B16 (murine) B8, BIO, MEL57 and ADLER
Time (h)
Figure 1 Concentrations of MTX and 70H-MTX
assayed by HPLC in the plasma of patient J.D.
during and following MTX infusion. ( 0) MTX,
(0 0) 70H-MTX.
(human). The acute lymphocytic leukemia line
(ALL), KM3, gave a similar profile. A second type
of profile, essentially flat, was found for human
melanoma MYJ15.
It is possible that differences in growth kinetics
between the cell lines might explain these two types
of dose-response profiles obtained for MTX. This
was explored by measurement of cell-kill following
different durations of exposure to 10-5M MTX
(Figure 3). The similarity of the 3 melanoma
profiles suggests that any differences in growth
kinetics do not affect the dose-response profile and
that the steeper line for MEL57 compared with B8
and BlO reflects the greater sensitivity of MEL57 to
MTX observed in Figure 2. Figure 3 also shows the
time profile for KM3 (ALL) cells exposed to MTX.
This profile is much steeper, indicating a greater
sensitivity to MTX reflecting the in vivo sensitivity.
Figure 4 shows dose-response profiles obtained
with 70H-MTX for the melanoma cell lines B8,
BlO, MEL57 and PG19. This metabolite is
cytotoxic for both the human and murine
melanomas but about two orders of magnitude less
effective than MTX.
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Figure 2 Response profile for melanoma cell lines
with increasing concentrations of MTX.
Competition of 70H-Methotrexate for the uptake of
[3HJ-Methotrexate
Figure 5a shows the time course of the intracellular
accumulation of [3H]-MTX following incubation of
a human melanoma cell line with 1.OpM or 1OpM
MTX. The rise to steady state in the intracellular
pool is approached more rapidly at the higher
MTX concentration. This indicates saturation of
the cellular transport mechanism at the higher
MTX concentration.
Competition of 70H-MTX for [3H]-MTX uptake
is indicated in Figure 5b. The results suggest 70H-
MTX competes with MTX for the same carrier.
Time of exposure to MTX (h)
Figure 3 Time course cell-kill of lines B8, BlO,
MEL57 and KM3 treated with 10- M MTX.
*- *B8, 0-0 BlO, *-*MEL57, A-A KM3.
The in vitro rescue assay was used, incubation being
continued for 7 days after reversal of MTX toxicity.
Metabolism of MTX and 70H-MTX by cells in
vitro We sought to determine whether differences
in the in vitro sensitivity to MTX were related to
the ability of cells to metabolise the drug. The
supernatant culture medium from cells incubated
alone, or treated with either MTX or 70H-MTX
for 24h, 7 days or 11 days was analyzed by HPLC.
Incubations were continued to 11 days to investigate
a possible relationship between cell lysis and MTX
metabolism. No correlation was found. These
studies showed that some of the melanomas
appeared to metabolise added MTX. The findings
are summarized in Table I. The metabolites
appear either as a shoulder on the main MTX peak
or as additional peaks in the optically-active
material eluting early from the column. The
metabolites found in the presence of MTX do not
correspond to any of the known metabolites. They
do not co-chromatograph with polyglutamyl
derivatives of MTX. No attempt was made during
the present study to characterize these compounds
further; however, the patterns were reproducible
within cell lines. Studies with 70H-MTX show that
this was more stable in the cultures and did not
100 -
I0--
0 -
_=
_4
lo-12MELANOMA RESPONSE TO METHOTREXATE 675
BOOlO
100-
at
u
10-10 10-4
70H-MTX concentration (M)
B0008
10-10 10-4
70H-MTX concentration (M)
en 1500-
In
0
x
IO 1000-
Q
0.
: 500-
cI)
(
b - °- ° °
... I I
10 20
Time (min)
PG19
100 -
C-
lo-10
C-)
.
10-4
MEL57
1000
U ()
-ii
0
- 500
x
Y, -19 LO)
10-10 10-4
70H-MTX concentration (M) 70H-MTX concentration (M)
Figure 4 Response profiles for melanoma cell lines
treated with increasing concentrations of 70H-MTX.
Table I Summary of HPLC analyses of MTX
and 70H-MTX metabolism in vitro by different
cell lines
Line MTX 70H-MTX
Medium alone No change No change
Murine melanoma
PG19 Altered Altered
Choriocarcinoma
BeWo No change Altered
JaR No change No change
Human melanoma
ADLER No change Altered
MYJ15 No change Altered
KOT No change Altered
B8 Altered No change
B1O No change No change
MEL57 No change No change
HPLC and culture methods are described in
the text
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Figure 5 (a) Time course of uptake of [3H]-MTX
into BlO melanoma cells in vitro. Cells were incubated
with a constant amount of [3H]-labelled drug and
unlabelled MTX added to the concentrations shown.
0-010-6M MTX, 0-0 10-5M MTX. (b)
Decreased uptake of [3H]-MTX (10- M) by B8
melanoma cells in vitro in the presence of 70H-MTX.
0-0 Control (no 70H-MTX), 0-0 106M 70H-
MTX, M-M 10-4 M 70H-MTX.
yield the same metabolite profiles as MTX.
Representative chromatograms obtained at 7 days
from PG19 cells which metabolise both MTX and
70H-MTX, and from B1O cells which metabolise
neither compound are shown in Figure 6. In each
experiment chromatograms from "control"
cultures, incubated for the same time intervals in
the absence of MTX and 70H-MTX showed only
the peak marked "M". In each case the baseline
was flat in the area of the metabolite peaks, at a
detector sensitivity of 0.08 AUFS. Supplementation
of culture extracts with MTX or 70H-MTX
immediately prior to HPLC gave peaks eluting in
the region of the profile assigned to the pure
compound.
Survivalfollowing leucovorin-rescue ofcells in vitro
Figure 7 shows that leucovorin rescues melanoma
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Figure 6 (a) HPLC profiles obtained from culture medium 11 days after incubation of PGl9 cells in the
presence of 10-6M MTX or 70H-MTX. M=substance present in medium, A,B,=unknown metabolites.
Position of methotrexate and 70H-MTX shown dotted. Control cultures showed only peak M.
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Figure 6 (b) HPLC profiles obtained from culture media 11 days after incubation of BlO cells in the
presence of 10-6M MTX or 70H-MTX. M =substance present in medium. Position of MTX and 70H-MTX
shown dotted. Control cultures showed only peak M.
cells from MTX toxicity in vitro. The B10 cells
resume growth following the addition of leucovorin
to the culture medium 24h after the application of
10-6M MTX. For comparison a choriocarcinoma
cell, JaR, was included as an example of a cell line
from a tumour known to be sensitive to MTX in
vivo. The in vitro rescue by leucovorin of the
choriocarcinoma resembles the B10 melanoma
though an earlier response is apparent.
A differential response was observed by titrating
MTX-inhibited cultures with increasing
concentrations of leucovorin. Figure 8 shows that
the choriocarcinoma JaR and B8 melanoma were
rescued by leucovorin and gave similar profiles. We100 -
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Figure 7 Rescue by leucovorin of human melanoma and choriocarcinoma cells from toxicity of MTX in
vitro. 0-0 B1O melanoma plus leucovorin, 0-0 B1O melanoma minus leucovorin, * * JaR
choriocarcinoma plus leucovorin, ] Ol JaR choriocarcinoma minus leucovorin. The in vitro rescue assay was
used. Cells were exposed to 10-6M MTX for 24h and toxicity reversed in the cultures indicated (plus
leucovorin). The remaining cultures were put through the same rescue procedure but no leucovorin was added
(minus leucovorin).
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Figure 8 Enhanced rescue by increasing
concentrations of leucovorin. 0 0 B8 melanona,
0 O JaR choriocarcinoma, A * KM3 (ALL).
The in vitro rescue method was used. Cells were
exposed to 10-6 M MTX for 24h. Toxicity was
reversed and incubation continues for 7 days in the
presence of leucovorin as shown on the abscissa.
did not find leucovorin-rescue using the BeWo
choriocarcinoma. KM3 (ALL) cells showed a
rescue profile similar to JaR and B8 cells. The
critical nature of the molar ratio of MTX to
leucovorin in vitro is illustrated by an experiment
(data not shown) in which rescue by the standard
leucovorin method was ineffective for B10 cells
when the concentration of MTX was raised to
5 xl0- M from the concentration of 106M used
in the experiments shown in Figure 7.
Discussion
This is the first study of melanoma patients treated
with MTX in which plasma concentrations of the
drug have been accurately monitored and the
accumulation of metabolities observed and
recorded. The results of these studies demonstrate
that the lack of response of melanoma to MTX
therapy is not due to failure to achieve adequate
plasma concentrations. The concentrations achieved
in our patients compared well with those known to
be effective in patients with other MTX-sensitive
tumours (see Breithaupt et al., 1982). In previous
clinical studies of MTX therapy in melanoma, total
doses of 2 gm 2 of MTX over 6h were used
(Karakousis & Carlson, 1979) rather than 1.5g over
24h in our study. It is likely therefore that in these
earlier studies even higher plasma concentrations
may have been achieved. Inadequate plasma
concentrations of MTX cannot therefore be the
cause of the failure of MTX therapy to kill
melanoma cells in vivo.
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We have also shown that 2 melanoma cell lines
studied (B8 and B0) take up MTX from the
culture medium and that there is competition for
MTX uptake by 70H-MTX (Figures 5a and 5b).
This finding suggests that the presence of 70H-
MTX could lead to reduced toxicity of MTX at
later stages of an infusion and thus reduce the time
for which the cells are exposed to adequate
concentrations of MTX. However, the
concentrations of 70H-MTX found in vivo in
plasma did not exceed those of MTX until 8 h after
the start of the infusion by which time the
intracellular concentration of MTX would be
expected to be high.
Studies of the in vitro metabolism of MTX
showed variable results depending upon the cell line
investigated. Cultures of ADLER, MYJ15, KOT,
B1O and MEL57 consistently failed to show
metabolism of MTX in the medium, whereas
cultures of B8 and PG19 metabolised the
compound. However, the substances subsequently
identified in the medium did not correspond on
chromatographic analysis to any of the known
MTX metabolites so far identified in vivo. In
particular they were not MTX polyglutamates,
which are known to be the major intracellular
metabolites (Galivan, 1979). There was no
correlation between those melanoma cell lines
which metabolised MTX and resistance or
sensitivity to it.
We have shown (Figure 2) that MTX arrests cell
division at a concentration of 10-8 M and that
following exposure to 10 6M methotrexate for 24h
there was no recovery of cell division up to 11 days
after removal of MTX (Figure 7).
We have also demonstrated that leucovorin can
rescue melanoma cells in culture from the toxicity
of MTX. The concentrations used in our in vitro
experiments correspond to those reported for
murine ascitic tumours by Sirotnak et al. (1978).
These values might be expected to be found in vivo
using a standard regime, from which it is clear that
both melanoma and non-malignant cells could
benefit from leucovorin-rescue. The fact that the
choriocarcinoma JaR also responds to leucovorin-
rescue in vitro indicates that tetrahydrofolate-rescue
is not unique to melanoma and therefore probably
not the sole reason for the failure of
MTX/leucovorin therapy in patients with
melanoma. However KM3 (ALL) cells sensitive to
MTX in vivo showed considerable time dependency
in that they failed to respond to leucovorin-rescue
following 8 h of exposure to MTX.
The failure to rescue KM3 (ALL) cells in our
standard assay may be related to a more rapid cell
cycle than the melanoma lines used. Clinically this
would account for a larger fractional cell-kill before
the concentration of 70H-MTX reached sufficient
magnitude to interfere with cell-kill.
Our studies demonstrate competition by the
major in vivo metabolite, 70H-MTX, for the
uptake of MTX by melanoma in vitro. If this is
mirrored in vivo, after 12h further uptake of MTX
from the plasma would be inhibited by the higher
concentrations of 70H-MTX. In conjunction with
the response to leucovorin-rescue, the effect would
be to expose melanoma cells to MTX for a much
shorter period than suspected hitherto. This may go
some way towards explaining why these particular
tumours are non-responsive to the drug using
current therapeutic protocols.
In summary we have shown that the non-
response of melanoma cells in vivo is unlikely to be
related to the plasma MTX concentration, or to the
ability of these cells to metabolise it. The plasma
profile and in vitro data suggest that after 12h at
least two factors may contribute to the continued
survival of melanoma cells: the concentrations of
70H-MTX in plasma may be sufficient to inhibit
the further uptake of MTX by these cells; secondly,
leucovorin may rescue both viable melanoma cells
and host tissue cells when current protocols are
used. The additional possibility that melanoma in
vivo is afforded protection from MTX cytotoxicity
by as yet unidentified cell kinetic or biochemical
mechanisms, such as the presence of salvaging
metabolites (nucleosides or folates) remains to be
investigated.
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